The receiver-in-canal form factor sets the processing constraint in over-the-counter hearing aids: the silicon responsible for voice isolation must fit inside a housing small enough to rest behind the ear. That is the engineering position Anker is now entering. At IFA 2026, the company announced its first OTC hearing aids, built around the Thus chip it introduced in April.
From earbuds to hearing aids
The Thus chip's first commercial release was in consumer audio. Anker shipped it inside the Soundcore Liberty 5 Pro earbuds series, and when The Verge reviewed that product, a writer at the publication described the chip's voice isolation as the best they had heard on any audio product. Voice isolation is the load-bearing function in a hearing aid. That established performance baseline is what Anker is carrying into the OTC hearing aid category.
The RIC configuration places the device's main body behind the ear. Anker has not disclosed a retail price or a specific ship date. The company described availability as expected in coming months, per the IFA announcement.
A vacancy in the US OTC market
The entry arrives against a specific backdrop. LXE Hearing, parent company of Eargo and Lexie Hearing, two major OTC hearing aid manufacturers in the United States, announced its decision to end US operations and exit the OTC market roughly two months before Anker's IFA appearance. Two established names in the segment have left.
The disclosures that matter most are still absent: a price, a firm timeline, and any clinical or regulatory data that addresses the step from a consumer earbud to a hearing health device.